Khinh Ranh Voong1, Benjamin Farnia1, Qianghu Wang1, Dershan Luo1, Mary F McAleer1, Ganesh Rao1, Nandita Guha-Thakurta1, Anna Likhacheva1, Amol J Ghia1, Paul D Brown1, Jing Li1. 1. Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston, Texas (K.R.V., B.F., Q.W., M.F.M., A.L., A.J.G., P.D.B., J.L.); Department of Radiation Physics , The University of Texas MD Anderson Cancer Center , Houston, Texas (D.L.); Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston, Texas (G.R.); Department of Radiology , The University of Texas MD Anderson Cancer Center , Houston, Texas (N.G.-T.).
Abstract
BACKGROUND: Brainstem metastases (BSMs) represent a significant treatment challenge. Stereotactic radiosurgery (SRS) is often used to treat BSM. We report our experience in the treatment of BSM with Gamma Knife SRS (GK_SRS). METHODS: The records of 1962 patients with brain metastases treated with GK_SRS between 2009 and 2013 were retrospectively reviewed. Seventy-four patients with 77 BSMs and follow-up brain imaging were identified. Local control (LC), overall survival (OS), progression-free survival (PFS), and toxicity were assessed. RESULTS: Median follow-up was 5.5 months (range, 0.2-48.5 months). Median tumor volume was 0.13 cm3 (range, 0.003-5.58 cm3). Median treatment dose was 16 Gy (range, 10-20 Gy) prescribed to 50% isodose line (range, 40%-86%). Crude LC was 94% (72/77). Kaplan-Meier estimate of median OS was 8.5 months (95% CI, 5.6-9.4 months). Symptomatic lesions and larger lesions, especially size ≥2 cm3, were associated with worse LC (HR = 8.70, P = .05; HR = 14.55, P = .02; HR = 62.81, P < .001) and worse OS (HR = 2.00, P = .02; HR = 2.14, P = .03; HR = 2.81, P = .008). Thirty-six percent of BSMs were symptomatic, of which 36% (10/28) resolved after SRS and 50% (14/28) had stable or improved symptoms. Actuarial median PFS was 3.9 months (95% CI, 2.7-4.9 months). Midbrain location was significant for worse PFS (HR = 2.29, P = .03). Toxicity was low (8%, 6/74), with size and midbrain location associated with increased toxicity (HR 1.57, P = .05; HR = 5.25, P = .045). CONCLUSIONS: GK_SRS is associated with high LC (94%) and low toxicity (8%) for BSMs. Presence of symptoms or lesion size ≥ 2 cm3 was predictive of worse LC and OS.
BACKGROUND: Brainstem metastases (BSMs) represent a significant treatment challenge. Stereotactic radiosurgery (SRS) is often used to treat BSM. We report our experience in the treatment of BSM with Gamma Knife SRS (GK_SRS). METHODS: The records of 1962 patients with brain metastases treated with GK_SRS between 2009 and 2013 were retrospectively reviewed. Seventy-four patients with 77 BSMs and follow-up brain imaging were identified. Local control (LC), overall survival (OS), progression-free survival (PFS), and toxicity were assessed. RESULTS: Median follow-up was 5.5 months (range, 0.2-48.5 months). Median tumor volume was 0.13 cm3 (range, 0.003-5.58 cm3). Median treatment dose was 16 Gy (range, 10-20 Gy) prescribed to 50% isodose line (range, 40%-86%). Crude LC was 94% (72/77). Kaplan-Meier estimate of median OS was 8.5 months (95% CI, 5.6-9.4 months). Symptomatic lesions and larger lesions, especially size ≥2 cm3, were associated with worse LC (HR = 8.70, P = .05; HR = 14.55, P = .02; HR = 62.81, P < .001) and worse OS (HR = 2.00, P = .02; HR = 2.14, P = .03; HR = 2.81, P = .008). Thirty-six percent of BSMs were symptomatic, of which 36% (10/28) resolved after SRS and 50% (14/28) had stable or improved symptoms. Actuarial median PFS was 3.9 months (95% CI, 2.7-4.9 months). Midbrain location was significant for worse PFS (HR = 2.29, P = .03). Toxicity was low (8%, 6/74), with size and midbrain location associated with increased toxicity (HR 1.57, P = .05; HR = 5.25, P = .045). CONCLUSIONS: GK_SRS is associated with high LC (94%) and low toxicity (8%) for BSMs. Presence of symptoms or lesion size ≥ 2 cm3 was predictive of worse LC and OS.
Authors: Jeremy M Kilburn; Thomas L Ellis; James F Lovato; James J Urbanic; J Daniel Bourland; J Daniel Bourland; Michael T Munley; Allan F Deguzman; Kevin P McMullen; Edward G Shaw; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2014-02-07 Impact factor: 4.130
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Kevin Shiue; Gene H Barnett; John H Suh; Michael A Vogelbaum; Chandana A Reddy; Robert J Weil; Lilyana Angelov; Gennady Neyman; Samuel T Chao Journal: Neurosurgery Date: 2014-04 Impact factor: 4.654
Authors: Mustafa Aziz Hatiboglu; Eric L Chang; Dima Suki; Raymond Sawaya; David M Wildrick; Jeffrey S Weinberg Journal: Neurosurgery Date: 2011-10 Impact factor: 4.654
Authors: Stéphane Fuentes; Christine Delsanti; Philippe Metellus; Jean Claude Peragut; François Grisoli; Jean Regis Journal: Neurosurgery Date: 2006-01 Impact factor: 4.654
Authors: Shlomo A Koyfman; Rahul D Tendulkar; Samuel T Chao; Michael A Vogelbaum; Gene H Barnett; Lilyana Angelov; Robert J Weil; Gennady Neyman; Chandana A Reddy; John H Suh Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-03 Impact factor: 7.038
Authors: José G Lorenzoni; Daniel Devriendt; Nicolas Massager; Françoise Desmedt; Stéphane Simon; Paul Van Houtte; Jacques Brotchi; Marc Levivier Journal: Surg Neurol Date: 2008-04-24
Authors: Daniel M Trifiletti; Cheng-Chia Lee; William Winardi; Nirav V Patel; Chun-Po Yen; James M Larner; Jason P Sheehan Journal: J Neurooncol Date: 2015-09-04 Impact factor: 4.130
Authors: Ajay Patel; Homan Mohammadi; Tuo Dong; Kevin Ren-Yeh Shiue; Douglas Frye; Yi Le; Shaheryar Ansari; Gordon A Watson; James C Miller; Tim Lautenschlaeger Journal: CNS Oncol Date: 2017-12-14